Patents by Inventor Aysegul Sahin

Aysegul Sahin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20190360057
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: June 18, 2019
    Publication date: November 28, 2019
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
    Patent number: 10378058
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: August 13, 2019
    Assignee: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20140112917
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 24, 2014
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20120039875
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: July 15, 2011
    Publication date: February 16, 2012
    Applicant: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
    Patent number: 7981618
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: July 19, 2011
    Assignee: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER
    Publication number: 20110150868
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: November 10, 2010
    Publication date: June 23, 2011
    Applicant: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20080311573
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: June 25, 2007
    Publication date: December 18, 2008
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas System
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai, Funda Meric, Aysegul Sahin, Gordon B. Mills
  • Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
    Publication number: 20050287543
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Application
    Filed: November 5, 2004
    Publication date: December 29, 2005
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco Esteva, Aysegul Sahin
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20030124128
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: June 21, 2002
    Publication date: July 3, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, Gabriel N. Hortobagyi, Lajos Pusztai, Funda Meric, Aysegul Sahin, Gordon B. Mills